In November, Pfizer said clinical trial data indicated the single-dose vaccine, called RSVpreF, was nearly 82 percent effective at preventing severe illness from RSV in infants through the first 90 days of life. Through the first six months of life, it was nearly 70 percent effective. There is currently no approved RSV vaccine.
“If approved, RSVpreF would help protect infants at their first breath from the devastating effects of this infectious disease, which though well-known, has been particularly evident throughout this RSV season,” Annaliesa Anderson, PhD, Pfizer’s senior vice president and chief scientific officer of vaccine research and development, said in a statement. “We look forward to progressing the review of Pfizer’s RSV maternal vaccine candidate with the FDA and other regulatory authorities, given its significant potential to positively contribute to global health in the prevention of RSV in infants.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
